Zhitong Finance App learned that on November 6, Guichuang Tongqiao Medical Technology Co., Ltd. (stock code: 02190, hereinafter referred to as “Guichuang Tongqiao”), a leading domestic vascular interventional medical technology company, issued an announcement to jointly strategically invest with GL Capital (GL Capital) in Xianjian Technology (stock code: 01302, hereinafter referred to as “Xianjian Technology”). The two sides have deeply complementary layouts in the four major business areas of peripheral vascular intervention, neurovascular intervention, aortic vascular intervention, and structural heart disease. Relying on this advantage, this strategic investment is expected to integrate the parties' resources in R&D and innovation, product portfolio and global commercialization to lay the foundation for building China's leading full-vascular and structural heart disease intervention platform, and further enhance the competitiveness of Chinese brands in the international market.
According to the relevant agreement, Guichuang Tongqiao and Telford Capital will jointly fund the establishment of GL Lighthouse Two Investment Limited (“Lighthouse Two”) to subscribe for newly issued shares of Xianjian Technology for a total of approximately HK$1,482 billion. After the transaction is completed, Lighthouse Two will hold about 16.7% of the total shares issued by Xianjian Technology after the additional issuance, making it the single largest shareholder of Xianjian Technology. Among them, Guichuang Tongqiao plans to invest about HK$889 million to hold 60% of Lighthouse Two's shares. In addition, Telford Capital plans to subscribe for 39.8 million shares newly issued by ChuangTongqiao at HK$22 per share, accounting for 10.8% of the company's total shares (excluding treasury shares) after the current issuance, providing financial support for the company to further increase its holdings in Xianjian Technology and overseas business development in the future. The subscription price was a 13.5% premium over the closing price on the day of the transaction announcement, and a 15.4% premium over the average closing price on the first five trading days of the announcement, fully demonstrating Telford Capital's recognition of the long-term development of Guichuang Tongqiao.
In the future, Guichuang Tongqiao and Telford Capital will further increase their shares in Xianjian Technology, accelerate business development, optimize resource allocation, improve operational efficiency, and enhance overall competitiveness and global commercialization capabilities. Furthermore, Guichuang Tongqiao intends to promote mergers between the two sides in the future to build China's leading full-vascular and structural heart disease intervention platform.
Complementary core business advantages to improve the layout of full-vascular and structural cardiac intervention
Xianjian Technology is a leading domestic cardiovascular and peripheral vascular interventional medical device company. It has deep technical accumulation and comprehensive product layout in the field of aortic intervention and structural heart disease. Xianjian Technology was listed on the Hong Kong Stock Exchange in 2011. Currently, it has more than 50 registration certificates in China, and 20 products have been approved to enter the national “green channel” for innovative medical devices. Xianjian Technology continues to promote a high-quality global intellectual property layout. As of June 30, 2026, a total of 2,608 valid patent applications have been submitted, of which 1,370 have been authorized.
In the field of aortic intervention, Xianjian Technology has taken the lead in building the world's industry's leading and most complete overall solution for full aortic intravenous treatment, covering the three key technical fields of intravenous reconstruction of the arch branch, visceral branch, and internal iliac artery. It has been well received by clinicians at home and abroad, and has a leading share in the domestic market. Many of the world's first products, such as the G-Branch thoracoabdominal aortic stent system, the Concave Supra integrated three-branch arch reconstruction system, and the SureCham aortic arch single branch laminating stent system, focus on unmet clinical needs and continue to lead technological innovation in aortic intravenous treatment. In the field of structural heart disease, the core products of Xianjian Technology include LamBRe, LaXible two-generation left atrial occluder and third-generation congenital heart disease occluder series products. It continues to meet different treatment needs through differentiated product strategies, and has maintained an important position in the domestic market for a long time.
Guichuang Tongqiao is a leading domestic interventional vascular medical technology company. It owns the two major brands “Guichuang Medical” and “Tongqiao Medical”, which focus on the fields of peripheral vascular intervention and neurovascular intervention respectively. As one of the few domestic enterprises that can provide full product solutions in two major fields, the company has formed a complete platform capability covering R&D innovation, product development and large-scale commercialization. Since 2025, Guichuang Tongqiao has added 6 new products to enter the national “green channel” for innovative medical devices. Relying on an efficient operating system and large-scale commercialization advantages, Guichuang Tongqiao has covered more than 3,500 domestic hospitals and commercialized in 70 overseas countries and regions, and its global operation capabilities continue to increase.
This strategic investment will give full play to the complementary advantages of the two sides in terms of core technology, product layout and commercialization capabilities, promote the deep integration of superior resources, build a full-vascular and structural heart disease intervention platform covering the four core business areas, further expand the business scale, strengthen the leading position in the industry, and enhance competitiveness in the global market.
Accelerate global business expansion and enhance the competitiveness of Chinese brands in the international market
In recent years, Guichuang Tongqiao has continued to advance its internationalization strategy, and its international business has maintained strong growth. In the first half of 2026, the company's international business revenue increased 349.3% year-on-year. The company's products were commercialized in 70 overseas countries and regions, and the global channel network covered more than 135 countries and regions. Guichuang Tongqiao continues to deepen the layout of key markets in Europe, Latin America and Asia, and enhance global market access and commercialization capabilities. Through the strategic acquisition and integration of German vascular interventional medical device company Optimed, the company has further strengthened its localized operation capabilities in Europe.
Xianjian Technology has a mature global sales network and an international operating foundation. Currently, it has 7 overseas subsidiaries, and the sales network covers nearly 120 countries and regions around the world. In 2025, Xianjian Technology's overseas revenue was nearly RMB 400 million, an increase of about 14.4% over the previous year, accounting for nearly 30% of total revenue. Among them, the European and Asian markets are its main source of overseas revenue, which shows strong competitiveness in the international market.
This strategic investment will create conditions for the two sides to further integrate global R&D and marketing resources, give full play to the complementary advantages of the two sides in product portfolios, market channels and operating systems, enhance the competitiveness of Chinese brands in the international market, and accelerate the construction of a globally competitive Chinese full-vascular and structural heart disease intervention platform.
Dr. Zhao Zhong, Chairman of Guichuang Tongqiao, said, “This strategic investment is an important milestone in Guichuang Tongqiao's construction of a leading full-vascular and structural heart disease intervention platform in China. By complementing the advantages of Xianjian Technology, Guichuang Tongqiao will further expand from the field of peripheral and neurovascular intervention to the field of aortic intervention and structural heart disease, forming a better business layout and expanding long-term development space. At the same time, relying on Guichuang Tongqiao's mature operating system and global layout, we are confident that we will further develop our business collaboration and scale advantages, enhance overall competitiveness, and accelerate our progress towards the world's leading innovative medical technology enterprise.”
Mr. Li Zhenfu, founding partner and CEO of Telford Capital, said, “Telford Capital has been deeply involved in the Chinese healthcare industry for many years and has always been committed to supporting the growth of outstanding enterprises through long-term capital and deep empowerment. We have long been optimistic about the development prospects of China's interventional vascular medical device industry and the global growth potential of China's innovative medical device companies. Using this strategic investment as an opportunity, Telford Capital will join forces with superior resources from all parties to help accelerate the achievement of the common strategic goals of an internationally competitive full-vascular and structural heart disease intervention platform. In the future, we will continue to make full use of our advantages in capital and industrial resources to support enterprises to enhance their competitiveness and accelerate global development.”
Mr. Xie Yuehui, founder of Xianjian Technology, said, “The introduction of this strategic investment highlights the high recognition by industry and capital of Xianjian Technology's technological innovation capabilities, market leadership position, and long-term growth value. Xianjian Technology and Guichuang Tongqiao are highly complementary in terms of business layout, product portfolio and market channels. This strategic initiative will open up a new development pattern for Xianjian Technology, promote deep collaboration of products, technology and superior resources between the two sides, and further consolidate its leading position in the industry. I will serve as a senior consultant for Xianjian Technology. Relying on nearly 30 years of industry accumulation, I will continue to empower the company's long-term development and accompany Xianjian Technology to a higher stage of development.”